245
Participants
Start Date
June 14, 2023
Primary Completion Date
January 1, 2026
Study Completion Date
December 15, 2026
Ivosidenib 500mg Oral Tablet
Provided as tablets, taken orally as two 250mg tablets once daily.
Azacitidine
Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
COMPLETED
AKH - Medizinische Universität Wien, Vienna
COMPLETED
Klinikum Wels-Grieskirchen GmbH, Wels
RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
CHU CAEN - Hôpital de la Côte de Nacre, Caen
RECRUITING
IRCCS Ospedale Policlinico San Martino, Genova
RECRUITING
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia
RECRUITING
CHU de Toulouse pt, Toulouse
NOT_YET_RECRUITING
CHU Rennes - Hopital Pontchaillou, Rennes
RECRUITING
"IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori - IRST", Meldola
NOT_YET_RECRUITING
CHU Angers - Hôpital Hôtel Dieu, Angers
RECRUITING
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia
RECRUITING
Meander Medisch Centrum, Amersfoort
RECRUITING
Amsterdam UMC, Amsterdam
NOT_YET_RECRUITING
Rijnstate, Arnhem
RECRUITING
Universitair Medisch Centrum Groningen, Groningen
Servier Affaires Médicales
INDUSTRY